EndoTimes

*Life with Endometriosis for Victims by Victims Not for Profit

Endometriosis ~ Abdominal Pain ~ Endo ~ Scar Tissue ~ Adhesions ~ Infertility ~ Hysterectomy
Showing posts with label endometriomas. Show all posts
Showing posts with label endometriomas. Show all posts

Wednesday, April 09, 2014

UPCI/MWRI researchers to present results of immune gene profile exploring endometriosis and cancer


Published on April 7, 2014 at 8:42 AM · No Comments
Some women with endometriosis, a chronic inflammatory disease, are predisposed toovarian cancer, and a genetic screening might someday help reveal which women are most at risk, according to a University of Pittsburgh Cancer Institute (UPCI) study, in partnership with Magee-Womens Research Institute (MWRI).
Monday at the American Association for Cancer Research (AACR) Annual Meeting 2014, UPCI and MWRI researchers will present the preliminary results of the first comprehensive immune gene profile exploring endometriosis and cancer.
"A small subset of women with endometriosis go on to develop ovarian cancer, but doctors have no clinical way to predict which women," said senior author Anda Vlad, M.D., Ph.D., assistant professor of obstetrics, gynecology and reproductive sciences at MWRI. "If further studies show that the genetic pathway we uncovered is indicative of future cancer development, then doctors will know to more closely monitor certain women and perhaps take active preventative measures, such as immune therapy."
Read more: http://www.news-medical.net/news/20140407/UPCIMWRI-researchers-to-present-results-of-immune-gene-profile-exploring-endometriosis-and-cancer.aspx
Posted by itsme at 7:12 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: adhesions, cancer link, Chronic pain, chronic pelvic pain, endo, endometriomas, ovarian cancer, ovarian cyst, pain, pelvic pain, scar tissue

Monday, March 31, 2014

Eve's Daughters, or, Go With the Flow

In the beginning, there was pain.
My periods began when I was 13-years-old, and I only remember them accompanied with pain. I bled heavily each month for six to eight days. As I got older, I would find myself passed out on my bedroom or bathroom floor from painful cramps. I would pass heavy blood clots, was often lightheaded, and regularly was prescribed iron supplements and over-the-counter medications like ibuprofen. When Alleve came on the market, I was thrilled to try a new pain reliever. They would dull, but never eradicate, the pain. My periods were always preceded with hefty bouts of PMS; I suffered from bloating, fatigue, headaches, skin rashes, and swelling in my knees and fingers.

When I'd report these symptoms to my doctor, he told me that periods can be like that. Some girls have problems, others don't. I just happened to be one of the girls who had a problem period. My mother told me the same thing, adding, "That's what my mother told me. It was like that for me and for other girls I knew growing up, too." As Carol Pearson discusses in her TEDTalk, as Zora Neale Hurston wrote inTheir Eyes Were Watching God ("Black women are the mules of the world"), as Eve was told after she fed into her curiosity and took a bite of that forbidden fruit, I learned -- whether the lesson was intended to be learned this way or not -- that being a girl, becoming a woman, was painful. And I had to live with that pain. I had to learn to handle pain.

And so I did. I went with the flow.

What I didn't know was that I had endometriosis.Endometriosis is a disease that affects 10 percent of women globally. It knows no race, class, or socioeconomic status. Some doctors refer to endometriosis as a benign cancer. Padma Lakshmi, model and co-founder of the Endometriosis Foundation of America, describes the disease as "a web, like a vapor, like weeds in a garden that permeate everything, and stain everything. And metaphorically as well as clinically what you have to go and do, whether it is with laparoscopy or therapy or just understanding and support, is you have to go in there... and get rid of it. Not only getting rid of it in the womb, but getting rid of it in the heart and the mind."
Read the rest http://www.huffingtonpost.com/nicole-brittingham-furlonge/eves-daughters-or-go-with_b_5010896.html
Posted by itsme at 1:12 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: ARD, Chronic pain, chronic pelvic pain, endo, endometriomas, Gynecologic Health, hysterectomy, implants, pelvic pain, scar tissue

Sunday, March 16, 2014

Transvaginal hydrolaparoscopy. as diagnostic tool Endometriosis Adhesions

JSLS. 2012 Jul-Sep;16(3):461-5. doi: 10.4293/108680812X13462882736295.

Transvaginal hydrolaparoscopy.

Ezedinma NA1, Phelps JY.

Author information

Abstract

Transvaginal hydrolaparoscopy (THL) is being performed regularly in Europe and China, but rarely in the United States. The reasons may be physicians' unfamiliarity with the procedure and their uneasiness over potential rectal puncturing due to the proximity of the rectum to the vaginal trocar insertion site. THL has the advantage over hysterosalpingography (HSG) in that it allows for direct visualization of the tubal mucosa in addition to determining tubal patency. THL has advantages over traditional laparoscopy in that it does not require an abdominal incision and has the capability of being conducted in an outpatient office setting with local anesthesia. Studies have shown that THL has comparable accuracy to laparoscopy with 96.1% concordance between THL and laparoscopic findings. THL may be combined with chromopertubation and salpingoscopy. In addition to diagnostic purposes, THL may be used for operative intervention including adhesiolysis, endometriosis ablation, and ovarian drilling. Studies from France and China report the occurrence of rectal injury from 0% to1%. Despite the advantages of THL and low reports of rectal injury, THL has not gained popularity in the United States. The purpose of this article is to familiarize gynecologists in the United States with THL.
PMID:
 
23318074
 
[PubMed - indexed for MEDLINE] 
PMCID:
 
PMC3535799
 
Free PMC Article
Images from this publication.See all images (1)Free text

Figure 1.

Publication Types, MeSH Terms

LinkOut - more resources

Posted by itsme at 8:55 PM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: adhesion related disorder, adhesions, ARD, endo, endometriomas, Endometriosis cancer link, infertility, scar tissue, surgical procedure

Transvaginal endoscopy and small ovarian endometriomas: unravelling the missing link?

Gynecol Surg. 2014;11:3-7. Epub 2013 Oct 17.
Gordts S, Puttemans P, Gordts S, Valkenburg M, Brosens I, Campo R.

Author information

Abstract

The incidence of endometriosis in the infertile female is estimated to be between 20 and 50 %. Although the causal relationship between endometriosis and infertility has not been proven, it is generally accepted that the disease impairs reproductive outcome. Indirect imaging techniques and transvaginal laparoscopy now offer the possibility of an early stage diagnosis. Although it remains debated whether the disease is progressive, treatment in an early stage is recommendable as it carries less risk for ovarian damage, hence premature ovarian failure. Under water, inspection with the technique of transvaginal hydrolaparoscopy (THL) accurately shows the invagination of the ovarian cortex as minimal superficial lesions but with the presence of well-differentiated endometrial like tissue at the base, the lateral walls and especially the inner edges of the small endometrioma. An inflammatory environment is responsible for the formation of connecting adhesions with the broad ligament and lateral wall with invasion of endometrial-like tissue and formation of adenomyotic lesions. In around 50 % of the small endometriomas, adhesiolysis is necessary at the site of invagination with opening of the cyst, to free the chocolate content and hereby recognize the underlying endometrioma. The detailed inspection of these early-stage endometriotic lesions at THL reunites the hypothesis of Sampson with the observation of Hughesdon.

KEYWORDS:

Endometrioma, Endoscopy, Hydroflotation, Ovarian endometriosis, Pathogenesis, Surgery, Transvaginal hydrolaparoscopy
PMID:
 
24611037
 
[PubMed]

http://www.ncbi.nlm.nih.gov/pubmed/24611037
Posted by itsme at 11:22 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: adhesion related disorder, adhesions, ARD, Chronic pain, endo, endometriomas, endometriosis, scar tissue

Saturday, March 15, 2014

Living With Endometriosis

Thank you!
One of the best Endometriosis Videos I have ever seen. You did a great job and our best wishes to you.
https://www.youtube.com/watch?v=bVZ8nXVtlvU


Posted by itsme at 6:50 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: ARD, Chronic pain, dioxin, endo, endometriomas, endometriosis, Endometriosis cancer link, killer cramps, lesions, pcbs, pelvic pain, scar tissue

Saturday, March 08, 2014

Fight like a girl! Endometriosis

These guys are great, Visit the site. Leave your story and help us create awareness of this vicious disease,
Fight Like A Girl Club Square Badge

http://www.fightlikeagirlclub.com
Posted by itsme at 7:25 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: adhesions, Chronic pain, dysmenorrhea, endo, endometriomas, endometriosis, pain, scar tissue, unnecessary hysterectomy

Thursday, December 05, 2013

Pesticides Linked to Endometriosis Risk


By NICHOLAS BAKALAR

Why some women and not others get endometriosis — the growth of uterine tissue outside the uterus that can cause pain and infertility — is not known, but researchers have come up with one possible contributing factor: pesticide poisoning.
Scientists studied 248 women with surgically confirmed endometriosis and 538 healthy controls. They measured blood levels of two pesticides, mirex and beta HCH, which persist in some fish and dairy products even though their use in the United States has been banned for decades. The studyappears online in Environmental Health Perspectives.
Read more: http://well.blogs.nytimes.com/2013/11/05/pesticides-linked-to-endometriosis/?_r=0
Posted by itsme at 6:25 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: Biomarker, dioxin, dysmenorrhoea, endo, endometriomas, endometriosis, infertility, lesions, Nodules, pain, pelvic pain

Tuesday, October 08, 2013

WHAT IF ENDOMETRIOSIS WAS A MEN’S HEALTH ISSUE?

The world would be a different place!
JORDAN DAVIDSON

As a health journalist and a co-founder of Endo Warriors, a support organization for women with endometriosis, I often get asked “what is endometriosis?”
Which is funny since it is estimated that 176 million women worldwide have endometriosis and yet no one knows about this global health issue.

http://www.hormonesmatter.com/endometriosis-mens-health-issue/

Visit Endo Warriors - https://www.facebook.com/endowarriorssupport
Posted by itsme at 7:45 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: adhesion related disorder, ARD, chronic pelvic pain, Cul-de-sac Obliteration, DIE, dysmenorrhoea, dyspareunia, endometriomas, endometriosis, fertility, pain, unnecessary hysterectomy

Sunday, March 04, 2012

International Endometriosis Awareness Month

Media release from Endometriosis New Zealand
Endometriosis New Zealand
Friday 02 March 2012, 2:06PM

Media release from Endometriosis New Zealand

International Endometriosis Awareness month will be launched in New Zealand at the International Women's Day Breakfast on Thursday 8 March, at the Ellerslie International Flower Show. All proceeds from the event will be donated to support Endometriosis New Zealand.

Deborah Bush (QSM), Chief Executive of Endometriosis New Zealand, said "endometriosis was one of the last medical taboo's of modern society. Awareness was essential as the disease affects approximately 126,000 girls and women in New Zealand and an estimated 176 million women worldwide." She said "using these statistics, it would potentially out-number all those with breast cancer, prostate cancer, diabetes I & II and AIDS in the 15 - 49 age group." The organisation relies solely on donations and fundraising to run its national services and programmes.

Tickets to the breakfast are now on sale and can be purchased from www.360endo.eventbrite.com

Endometriosis Facts

• Endometriosis (pronounced 'end-oh-me-tree-oh-sis') is a common disease affecting one in ten New Zealand women and girls
• It creates major human and financial burdens for individuals, families, health and welfare services and facilities, schools and work-place productivity
• Evidence shows that girls and women experience a diagnostic delay of 8+ years from first presentation of symptoms to a doctor
• Women are frequently misdiagnosed and may have undergone unnecessary and expensive investigations
• There are approximately 126,000 girls and women with endometriosis in New Zealand
• Canterbury women, in particular, are more vulnerable than ever as stress often makes chronic pain and symptoms worse. The demand on the services of Endometriosis New Zealand are greater than ever, however the ability to respond to the demand has been compromised by losses incurred through the cancellation of fund raising events from damage incurred by the Canterbury earthquakes.

http://www.nzendo.co.nz/

http://www.nzdoctor.co.nz/un-doctored/2012/march-2012/02/international-endometriosis-awareness-month.aspx
Posted by itsme at 4:09 AM 1 comment:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: Chronic pain, deep infiltrating endometriosis, dioxin, endo, endometriomas, endometriosis, excise, fertility, hope, lesions, Nodules, pelvic pain, questionable medical practices

Friday, December 09, 2011

Study Links Ovary Removal in Younger Women to Bone Thinning and Arthritis

Released: 12/6/2011 8:45 AM EST
Embargo expired: 12/8/2011 11:30 AM EST
Source: Johns Hopkins Medicine


Note to Reporters: The authors of this study will present their data during a press conference at the CTRC-AACR San Antonio Breast Cancer Symposium on Thursday, Dec. 8 at 11:30 AM, ET. The dial-in phone number for the press conference is (888) 647-7462.


Newswise — Having both ovaries removed before age 45 is strongly associated with low-bone mineral density and arthritis in later years, according to a new study by Johns Hopkins oncologists and epidemiologists. The analysis covered several thousand women who took part in a U.S. government-sponsored, multiyear national health study, and excluded women whose ovaries were removed due to cancer.

“This is one of the largest national studies, to my knowledge, that highlights the difference in bone-mineral density in women who have their ovaries removed at a young age. Our results suggest that such women should be monitored closely for osteoporosis,” says Kala Visvanathan, M.D., M.H.S., associate professor of oncology and epidemiology in the Johns Hopkins Bloomberg School of Public Health and Kimmel Cancer Center. Results of the study are expected to be presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10.

The investigators were interested in studying the long-term effects of ovary removal, known as oophorectomy, on bone health since the procedure is recommended to reduce ovarian and breast cancer risk in women at high risk for these diseases. Oophorectomy also is a common procedure in women who undergo hysterectomy, or womb removal. In the U.S., about 600,000 1 women per year undergo a hysterectomy, or womb removal, and about half of these women also have both ovaries removed. Hysterectomy is commonly performed in middle-aged women to treat symptoms of pain or bleeding caused by conditions, such as fibroids, endometriosis, or uterine prolapsed, or cysts. Women having hysterectomies for these benign conditions may also have their ovaries removed at the same time, believing that it will reduce cancer risk, according to Visvanathan.

Regardless of the reason for such surgery, however, the procedure has adverse effects, the Hopkins researchers say. Levels of estrogens and related hormones that are normally produced by the ovaries fall steeply after oophorectomy, bringing on menopause abruptly in women who are not yet postmenopausal. Estrogens help protect the body from aging and age-related disease, and physicians and epidemiologists over the past two decades have linked their premature loss to increased risks of parkinsonism, dementia, arthritis, and the brittle-bone condition known as osteoporosis.

For the study, Anne Marie McCarthy, a Ph.D. candidate at Hopkins’ Bloomberg School of Public Health, and Visvanathan used existing information from a health research database, called the third National Health and Nutrition Examination Survey (NHANES III). The information was gathered as part of a U.S.-sponsored epidemiological study conducted during 1988-94, and, among other health measures, it includes data from standard, X-ray-based measure of bone-mineral density in the hip and spine for thousands of women. “Using the NHANES III data, we set out to measure bone mineral density in women who’d had a bilateral oophorectomy compared with women with intact ovaries,” says McCarthy.

Of the data on 34,000 Americans aged two months and older included in the NHANES III study, McCarthy focused on more than 3,700 women aged 40 and over with no history of cancer. Most had intact ovaries; of the 560 women who had oophorectomy, about half had surgery before age 45.

McCarthy found that women who had both ovaries removed before age 45 had on average three percent lower bone mineral density than women with intact ovaries.

McCarthy examined arthritis risk, too, and found that 48 percent of women who had oophorectomies before age 45 reported an arthritis diagnosis, compared with only 32 percent for those with intact ovaries.

When McCarthy excluded women who had taken hormone replacement therapy (HRT), which normally counters the effects of lost ovarian hormones, these added risks became even higher. “Women who had had a bilateral oophorectomy before age 45 and didn’t take HRT were about twice as likely to get arthritis and three times as likely to have low-bone mineral density, compared with those with intact ovaries,” she says.

The NHANES III data represent snapshots of subjects’ health, and do not conclusively establish that oophorectomy causes lower bone mineral density, according to the researchers. But the Hopkins researchers’ analysis is consistent with previous studies, they say, and strongly suggests that oophorectomy can accelerate age-related conditions, such as osteoporosis – and thus shouldn’t be done without a clear medical reason. “The key factor may be the abrupt removal of ovarian hormones, in contrast with natural menopause in which there is a gradual decline, but that’s something we need to study further,” says Visvanathan.

Women with cancer and other medical conditions that necessitate oophorectomy, and women with specific genetic mutations that bring extremely high ovarian cancer risk, should still get their ovaries removed, she adds. “But they should be monitored closely for early signs of low-bone mineral density, so that osteoporosis can be prevented with the appropriate treatments.”

The research was funded by the Breast Cancer Research Foundation.

On the Web:
http://www.hopkinskimmelcancercenter.org/

CTRC-AACR San Antonio Breast Cancer Symposium: http://www.sabcs.org/

Reference:
1. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585770

http://www.newswise.com/articles/johns-hopkins-study-links-ovary-removal-in-younger-women-to-bone-thinning-and-arthritis
Posted by itsme at 5:45 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: adhesions, ARD, DIE, endometriomas, endometriosis, hysterectomy, low-bone mineral density, menopause, Postmenopausal, scar tissue, unnecessary hysterectomy

Thursday, December 08, 2011

Protagen Collaborates in Endometriosis Biomarker Project

Protagen Collaborates in Endometriosis Biomarker Project
Protagen AG
Protagen AG, a specialist for in-vitro diagnostics, has announced that it is to collaborate with Bayer HealthCare Pharmaceuticals on the clinical validation of Endometriosis biomarkers. The project will build on the results of the Endometriosis biomarker discovery study performed last year.

Endometriosis is a gynaecological condition which occurs in roughly 5-10% of women worldwide. It occurs when uterine cells grow outside of the uterine cavity, often on the ovaries. The debilitating condition can cause recurrent pelvic pain of varying severity, constipation, fatigue and infertility issues in sufferers.

Protagen has successfully developed the proprietary UNIarray® technology platform for the development of novel, non-invasive diagnostic tests based on auto-antibody signatures in human blood.

The ‘gold standard’ diagnostic test for endometriosis is currently laparoscopy, a visual inspection of the abdominal organs followed by surgical removal and examination of lesions. The collaborative project to be undertaken by Protagen AG and Bayer Healthcare Pharmaceutical, is aimed at employing the UNIarray® technology for the predictive diagnosis of Endometriosis.

“With the targeted advancement of the UNIarray® technology platform, Protagen has developed into a preferred partner for drug development companies”, states Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics at Protagen, “now we can directly support our collaboration partners in pharma and biotech in all clinical Phases I-IV with the development of therapy specific diagnostic assays. Besides Endometriosis, our technology is applied in autoimmune diseases like Multiple Sclerosis, chronic inflammatory diseases and cancer. Cooperation partners are, amongst others, Bayer, Biogen-Idec und SuppreMol”.

In order to understand the biochemical and molecular biological processes of Endometriosis, new technologies like UNIarray® are becoming increasingly important. Improving the predictive diagnosis of Endometriosis should help to improve patient’s quality of life.
Posted by itsme at 6:53 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: adhesions, Biomarker, Chronic pain, DIE, endo, endometriomas, endometriosis, Endometrium, investigation, lesions, pain, pelvic pain, scar tissue

Saturday, December 03, 2011

Rise in Dangerous Type of Ovarian Cancer

Poon Chian Hui - Straits Times Indonesia | November 18, 2011

More women in Singapore are coming down with an aggressive form of ovarian cancer whose symptoms are vague and survival rate low.

In 1988, 5.2 percent of all ovarian cancers were of the type called clear cell carcinoma. In 2007, the figure went up to 13.4 percent.

Less than 40 percent of women who get it survive, even when the cancer is detected early, said Associate Professor Tay Sun Kuie of the Singapore General Hospital (SGH).

In contrast, other types of ovarian cancer have a survival rate of as high as 70 percent when discovered early.

Prof Tay led a study which looked at the profiles of 256 ovarian cancer patients seen at SGH from 2004 to 2009, and examined national trends based on data from the Singapore Cancer Registry from 1988.

Ovarian cancer is the fifth most common among women in Singapore after breast, colorectal, lung and uterus, and nearly 300 are diagnosed with it every year.

It affects one out of 18 female cancer patients, and some 40 percent of cases occur in those aged 55 and above. The clear cell type usually crops up earlier, in those aged 40 onwards.

The symptoms for clear cell carcinoma are vague, but it has been found to occur in women who have painful and irregular periods and who are mysteriously losing weight or their appetite.

The study also found that women who were never pregnant are 14 percent more likely to get this aggressive cancer, compared with ovarian cancer patients who had at least one child.

There is also a link to endometriosis, a disorder where the womb lining responsible for menstruation is found outside the womb, leading to severe menstrual cramps, chronic pain in the pelvic region and infertility.

Patients who have the clear cell type are nearly five times more likely to have endometriosis than those with other types of ovarian cancer.

Clear cell carcinoma is the most lethal of all ovarian cancers. Even with surgery and chemotherapy, up to 80 percent of sufferers fail to improve, even if they were diagnosed at an early stage.

Prof Tay, a senior consultant in obstetrics and gynaecology, said the cancer cells have special genes that makes them more resistant to chemotherapy drugs. "Giving the cancer cells medicine is like giving them water - it doesn't kill them," he said.

SGH decided to research clear cell carcinoma because the cancerous cysts resemble ordinary ones in ultrasound and computed tomography (CT) scans.

Cysts in the ovaries are common and normally harmless.

"The cyst looks just like an empty fish bowl," said Prof Tay. "It can confuse doctors... because of the seemingly harmless appearance."

This was the case for a patient known only as Madam Lim in the study, which was first presented at the Singapore International Congress of Obstetrics and Gynaecology in August.

The 41-year-old manager, who was married but never pregnant, had a history of endometriosis.

When her pain flared up again, she underwent ultrasound and CT scans which revealed a large cyst measuring 15cm in diameter.

During the operation to remove it, doctors realized she actually had clear cell ovarian cancer.

Her condition is currently stable after treatment.

As doctors "cannot possibly take out every cyst in all women", Prof Tay hoped the study would help doctors in better diagnosing this cancer by pointing out, for example, the link with endometriosis.

He said women who experience an unexplained loss of appetite and worsening symptoms of endometriosis may want to seek medical advice early.

"This doesn't mean that one should be alarmist, but women ought to be more aware of changes in their body," he said.

Reprinted courtesy of Straits Times Indonesia. To subscribe to Straits Times Indonesia and/or the Jakarta Globe call 021 2553 5055.


http://www.thejakartaglobe.com/international/rise-in-dangerous-type-of-ovarian-cancer/479337#Scene_1
Posted by itsme at 8:01 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: Chronic pain, Cul-de-sac Obliteration, DIE, endo, endometriomas, endometriosis, Endometriosis cancer link, Endometrium, fertility, Gynecologic Health, lesions, pain, pelvic pain, scar tissue

Friday, December 02, 2011

Endometriosis Has Major Effect on Lives of Women

Posted by itsme at 6:35 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: adhesions, Chronic pain, DIE, dysmenorrhea, dyspareunia, endometriomas, endometriosis, Endometrium, fertility, menorrhagia, pelvic pain, scar tissue, unnecessary hysterectomy

Wednesday, November 30, 2011

Notice of Decision for Pr VISANNE® Canada

Notice of Decision for PrVISANNE®Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

(PDF Version - 23 K)
Contact: Bureau of Metabolism, Oncology and Reproductive Sciences

Date issued: November 7, 2011

On October 12, 2011, Health Canada issued a Notice of Compliance to Bayer Inc. for the drug product, Visanne.

Visanne contains the medicinal ingredient dienogest which is a progestin.

Visanne is indicated for the management of pelvic pain associated with endometriosis. The efficacy of Visanne has not been tested beyond 15 months.

Endometriosis is a gynaecological disease where endometrial tissue is found outside the uterine cavity, most commonly on the ovaries and the peritoneal surface. This tissue can cause inflammation and adhesions which result in chronic pelvic pain and often infertility. The cause of endometriosis remains unknown. Visanne reduces the endogenous production of estradiol and thereby suppresses the trophic effects of estradiol on both the eutopic and ectopic endometrium. When given continously, Visanne leads to a hyperprogestogenic and moderately hypoestrogenic endocrine environment causing initial decidualization of endometrial tissue. In addition to the estradiol-mediated effects Visanne also has direct antiproliferative, immunologic and antiangiogenic effects that contribute to the reduction of pelvic pain associated with endometriosis.

The market authorization was based on quality, non-clinical, and clinical information submitted. The efficacy and safety of Visanne were demonstrated primarily in three multicentre Phase III studies. All three studies enrolled patients with a confirmed diagnosis of endometriosis with various stages of disease severity. Assessment of pelvic pain associated with endometriosis was determined by using a visual analog scale (0-100 mm, where 0 mm represents no pain and 100 mm represents severe pain). The first study was a double-blind placebo-controlled study where 102 patients were treated orally (PO) with a Visanne 2 mg tablet once daily (OD) compared to 96 patients who were treated with a placebo, over a 12 week period. The second study was an open-label extension to the placebo-controlled study. The extension study included 168 women; 87 previously treated with Visanne (2 mg, PO, OD) and 81 previously treated with placebo. All 168 women received Visanne (2 mg, PO, OD) for an additional 52 weeks to assess the long-term efficacy of Visanne treatment. The third study compared Visanne (2 mg, PO, OD) to 3.75 mg leuprolide acetate administered intramuscularly every four weeks, where 120 patients received Visanne treatment and 128 patients received leuprolide acetate, for a 24-week treatment period. Results from all three studies demonstrated that treatment with Visanne produced clinically significant reductions in pelvic pain compared to baseline values. In the placebo-controlled study, following 12 weeks of treatment with Visanne, the mean reduction of pelvic pain compared to baseline was 27.4 ± 22.9 mm. The open-label extension study showed continued improvement in pelvic pain for up to 15 months. In the third active comparator study, Visanne demonstrated efficacy similar to leuprolide acetate in reducing pelvic pain associated with endometriosis. In all clinical studies, Visanne was generally well-tolerated.

Visanne (2 mg, dienogest) is provided in tablet form. The recommended dose of Visanne is one oral tablet per day, preferably taken at the same time each day, with some liquid as needed. Visanne tablets are intended for continuous administration regardless of any vaginal bleeding. Dosing guidelines are available in the Product Monograph.

Visanne is contraindicated in women with any of the conditions listed below, which are partially derived from information on other progestin-only preparations. Should any of the conditions appear during the use of Visanne, treatment must be discontinued immediately.

•Known or suspected pregnancy;
•Lactation;
•Active venous thromboembolic disorder;
•Arterial and cardiovascular disease, past or present [for example (e.g.) myocardial infarction, cerebrovascular accident, ischaemic heart disease];
•Diabetes mellitus with vascular involvement;
•Presence or history of severe hepatic disease as long as liver function values have not returned to normal;
•Presence or history of liver tumours (benign or malignant);
•Known or suspected sex hormone-dependent malignancies;
•Undiagnosed abnormal vaginal bleeding;
•Any ocular lesion arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual fields;
•Current or history of migraine with focal aura;
•Hypersensitivity to dienogest or to any ingredient in the formulation or component of the container.
Visanne should be administered under the conditions stated in the Product Monograph taking into consideration the potential risks associated with the administration of this drug product. Detailed conditions for the use of Visanne are described in the Product Monograph.

Based on the Health Canada review of data on quality, safety, and efficacy, Health Canada considers that the benefit/risk profile of Visanne is favourable for the indication stated above.

© 2011, Bayer Inc.
®VISANNE is a trademark used under license by Bayer Inc.

Notices of Decision (NDs) are produced in accordance with the Summary Basis of Decision (SBD) initiative. All NDs will be reproduced within the corresponding SBD, normally available within 5 months of product authorization.

http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/nd_ad_2011_visanne_132174-eng.php
Posted by itsme at 6:49 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: adhesion related disorder, ARD, Chronic pain, DIE, dysmenorrhea, dyspareunia, endo, endometriomas, endometriosis, Endometrium, menorrhagia, pain, pelvic pain, scar tissue, Visanne

Visanne® is the first oral treatment approved in more than 10 years for Canadian women with endometriosis

MORE FINANCIALS November 29, 2011 7:00 AM - General
Save Visanne® is the first oral treatment approved in more than 10 years for Canadian women with endometriosis~ Provides women with the first approved long-term, oral treatment option to relieve debilitating pelvic pain from endometriosis ~

TORONTO, Nov. 29, 2011 /CNW/ - There is now relief for Canadian women living with the pelvic pain associated with endometriosis. The symptoms of endometriosis, including severe menstrual cramps, painful intercourse, painful urination or bowel movements, and lower back or abdominal pain, take a toll on a woman's emotional health and overall quality of life. Bayer HealthCare announced that Visanne® (2 mg dienogest tablets) was approved by Health Canada for the management of pelvic pain associated with endometriosis. It is the first long-term, oral, progestin-only regimen specifically developed for women with endometriosis in more than 10 years.1

"Once diagnosed, endometriosis patients must use a treatment on a daily basis to cope with the immense pain of the disease," said Dr. Sony Singh, Director of Minimally Invasive Gynecology, Department of Obstetrics and Gynecology, University of Ottawa. "Visanne is an important management option for patients with the disease, as it is proven to relieve the chronic, debilitating pelvic pain caused by endometriosis including menstrual pain and pain during sexual intercourse. This is the first new treatment in more than a decade to help these women, which is encouraging."

Visanne® has been shown to provide effective pain relief in women with endometriosis, as clinical studies of up to 15 months duration, have proven that Visanne® is effective at relieving pelvic pain.2 Visanne® contains a novel progestin called dienogest, which suppresses the effects of estradiol on endometrial tissue and effectively reduces pelvic pain.3

The Impact of Endometriosis
Endometriosis is the growth of tissue, similar to the kind that lines the uterus every month, elsewhere in the abdomen. This excess tissue responds to the monthly menstrual cycle and when the tissue breaks down, it can lead to inflammation, causing pain. Common sites for endometrial growth are the ovaries, on the uterus and behind the uterus.4 The condition affects approximately 5 - 10 per cent of women of reproductive age.5 Pain associated with endometriosis can be excruciating and debilitating and is often the most difficult symptom for women with the disease.6

The disease can greatly impact a woman's social, professional and personal life, and women with endometriosis often experience a higher incidence of depression and emotional distress due to the uncertainty of diagnosis, unpredictability of symptoms and living a normal life.7

Recognize the Symptoms
Despite the high prevalence of endometriosis, there is a lack of general disease awareness and few women recognize the symptoms - thus causing a significant delay in diagnosis. Studies show it takes an average of three years from the time a woman has her first symptom to the time she discusses it with her doctor.8 It frequently takes up to 12 years for a woman to get a confirmed diagnosis from the first time she seeks help for her symptoms.9

"It is very common for women to live for several years with the severe pelvic pain of endometriosis before receiving an official diagnosis. This often means a delay in disease management consequently, negatively impacting their professional, social and psychological life," said Jan Silverman, The Endometriosis Network of Toronto (TENT). "It's important for women to learn about the symptoms of endometriosis, rather than just thinking pelvic pain is 'normal.' Women need to know that endometriosis is real and the pain can be treated, so it's important for them to speak with their doctors. The availability of a new treatment is good news and a step in the right direction."

The Facts on Visanne®
Visanne® (2 mg dienogest tablets) is indicated for the management of pelvic pain associated with endometriosis. Clinical trials regarding the efficacy of Visanne® have lasted up to 15 months.10

In clinical trials, Visanne® was generally well tolerated. The most frequent side effects reported were headache, breast discomfort including breast engorgement and breast pain. Undesirable effects, such as irregular bleeding, are more common during the first months of treatment with Visanne® and subside with continued treatment.2 Patients are encouraged to talk to their healthcare provider to see if Visanne® is right for them.

To learn more about endometriosis, visit www.endometriosisinfo.ca. For more information on endometriosis support groups from TENT, visit the group's Facebook page: http://www.facebook.com/group.php?v=info&ref=mf&gid=301016744454
.

About Bayer Inc.
Bayer Inc. (Bayer) is a Canadian subsidiary of Bayer AG, an international research-based group with core businesses in health care, crop science and innovative materials. Headquartered in Toronto, Ontario, Bayer Inc. operates the Bayer Group's HealthCare and MaterialScience businesses in Canada. Bayer CropScience Inc., headquartered in Calgary, Alberta operates as a separate legal entity in Canada. Together, the companies play a vital role in improving the quality of life for Canadians - producing products that fight diseases, protecting crops and animals, and developing high-performance materials for applications in numerous areas of daily life. Canadian Bayer facilities include the Toronto headquarters and offices in Montréal and Calgary.

Bayer Inc. has approximately 800 employees across Canada and had sales of $827 million CDN in 2010. Globally, the Bayer Group had sales of over 35 billion Euro in 2010. Bayer Inc. invested approximately $36 million CDN in research and development in 2010. Worldwide, the Bayer Group spent the equivalent of over 3.1 billion Euro in 2010 in R&D. For more information, go to www.bayer.ca.

Forward-Looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at http://www.bayer.com/
. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

References:
--------------------------------------------------------------------------------

1 Lupron Depot Canadian Product Monograph. http://www.abbott.ca/static/content/document/LUPRON-DEPOT-ENDO-PM-23MAR10.pdf.
 May 20, 2011.

2 Visanne Product Monograph. 2011. Page 21.

3 Visanne Product Monograph. 2011. Page 14.

4 SOGC.ca. What is Endometriosis? Available at http://www.sogc.org/health/health-endometriosis_e.asp
. Accessed November 1, 2011.

5 Endometriosis. Infertility Awareness Association of Canada. Available at: http://www.iaac.ca/content/endometriosis-1
. Accessed October 31, 2011.

6 Hummelshoj L. Medical needs in endometriosis. Gynaecology Forum 2010;15(2):5-7.

7 Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan. ESHRE guideline on the diagnosis and management of endometriosis. Human Reproduction 2005;20(10):2698-2704. Also available online at: http://guidelines.endometriosis.org/.


8 Diagnosis: http://www.womenshealthmatters.com/centres/pelvic_health/endometriosis/diagnosis/index.html . Accessed November 1, 2011.

9 SOGC Diagnosis and Management Guidelines. Available at: http://www.sogc.org/guidelines/documents/gui244CPG1007E.pdf.  Accessed November 1, 2011.

10 Visanne Product Monograph. 2011. Page 3.



For further information:
For more information or to arrange an interview, please contact:

Laine Jaremey Tiana DiMichele
GCI Group (Canada) Bayer Inc.
416-486-7224 416-240-5466
laine.jaremey@gcicanada.com

http://www.newswire.ca/en/story/886139/visanne-is-the-first-oral-treatment-approved-in-more-than-10-years-for-canadian-women-with-endometriosis
Posted by itsme at 6:45 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: ARD, Chronic pain, dysmenorrhea, dyspareunia, endo, endometriomas, endometriosis, Endometrium, hope, menorrhagia, pain, pelvic pain, Visanne

Saturday, November 26, 2011

Endometriosis

This patient education video explains endometriosis. Endometriosis is a common medical condition that affects women. The program covers anatomy, symptoms, causes, diagnosis, and treatment options.




Posted by itsme at 7:55 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: adhesion related disorder, ARD, Chronic pain, DIE, dysmenorrhea, dyspareunia, endo, endometriomas, endometriosis, Endometrium, ERC, fertility, scar tissue, unnecessary hysterectomy

Monday, November 21, 2011

Taking birth-control pills — but not for birth control

By Jennifer LaRue Huget
Oral contraceptives are quite the multi-taskers these days.

A new report finds that of the 11.2 million women ages 15 to 44 who use oral contraceptives, 86 percent do so primarily to prevent pregnancy, while the remaining 14 percent — 1.5 million women — take them solely for other reasons. Those reasons include easing menstrual cramps or pain, regulating menstrual cycles, relieving symptoms of endometriosis and controlling acne. The report further found that more than three quarters of a million women who take the pill report never having had sex.

The report was written and published by the nonprofit Guttmacher Institute (which works to “advance sexual and reproductive health and rights,” according to its Web site) and drawn from data collected through the federal National Survey of Family Growth.

The report could help clarify, or further muddy, the controversy over whether the federal government should require insurance companies to cover the cost of birth control, including oral contraceptives.

By Jennifer LaRue Huget | 07:00 AM ET, 11/18/2011

http://www.washingtonpost.com/blogs/the-checkup/post/taking-birth-control-pills--but-not-for-birth-control/2010/12/20/gIQAbKieVN_blog.html
Posted by itsme at 5:44 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: adhesion related disorder, ARD, endo, endometriomas, endometriosis, Endometrium, excise, lesions, Nodules, pain, pelvic pain, unnecessary hysterectomy

Sunday, November 20, 2011

'Top Chef' Host Padma Lakshmi On Dealing With Her Chronic Pain From Endometriosis

Padma Lakshmi, an author, model and Emmy-nominated host of Bravo's "Top Chef," suffered chronic pain every month for 23 years before she was finally diagnosed with endometriosis at age 36.

"I even had regular exams, and I had an ovarian cyst removed. They said everything would be better, but it didn't, and that was the tip of the iceberg," Lakshmi, now 41, said in an interview with HuffPost. "If I had been diagnosed at 20, or 25, the quality of my life would have been drastically different."

Endometriosis is actually quite common, affecting 8.5 million women in North America, though many are not diagnosed until their mid-20s, according to the Endometriosis Foundation of America, a non-profit organization Lakshmi co-founded with her doctor, Dr. Tamer Seckin, MD, to educate girls and young women about the condition. Just last month, the foundation held a conference to teach nurses about endometriosis, as they are often the first to see potential signs of the condition.

Undiagnosed and untreated, endometriosis causes abnormally painful cramping, bloating and nausea, and can even lead to infertility, according to the Mayo Clinic. It's often confused for ovarian cysts, pelvic inflammatory disease and irritable bowel syndrome. There is no cure for the condition, which occurs when the endometrium (the tissue that lines the inner part of the uterus) grows outside of the uterus, most commonly on the ovaries, bowel or the tissue that lines the pelvis, according to the Mayo Clinic. Depending on the pain, painkillers, hormone therapy, surgery and even hysterectomy are options for treating the condition.

Risk factors for the condition include having a shorter-than-normal menstrual cycle, having never given birth and having a family history (a mom, aunt or sisters) of the disease, the Mayo Clinic reported.

Lakshmi's in the family history camp. Her mother had undiagnosed endometriosis, and so when Lakshmi grew up experiencing the severe pain every month, she thought "it was just my lot in life."

Click here to read the rest: http://www.huffingtonpost.com/2011/11/15/padma-lakshmi-endometriosis-chronic-pain_n_1094003.htm l
Posted by itsme at 11:10 AM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: ARD, Chronic pain, DIE, dysmenorrhea, dyspareunia, endo, endometriomas, endometriosis, Endometrium, hope, laparoscopy, lesions, menorrhagia, pain, pelvic pain

Thursday, November 17, 2011

Endometriosis slowly emerges as a debilitating Disease for Women

Endometriosis slowly emerges as a debilitating Disease for Women
PDF | Print | E-mail

Written by Cleophas Mutinda




Imagine a pain in your abdomen so excruciating that you are unable to get out of bed for several days every month. That is horrible enough, but when it continues 12 times a year for more than 27 years, majority of people would agree it is cruel.

Most women with endometriosis will recognise this shocking scenario as not imaginary, but very real. They know the misery of pelvic pain and have poignant stories of how endometriosis has devastated their lives with terrible suffering. Many women feel angry or despondent about being robbed off a normal life during teenage, adulthood and even sometime a ruined motherhood.

Endometriosis is a gynaecological condition, which occurs when, cells like the ones (endometrial cells) lining inside of the uterus (womb) grow outside, usually on the surfaces of organs in pelvic and abdominal areas. It can be found within the peritoneal cavity, on the ovaries and the bowels or bladder. In extremely rare cases, endometriosis can be found in lungs or other parts of the body. Endometriosis can affect any menstruating woman, from time of her first period to menopause, regardless of race, ethnicity or socio-economic status. Endometriosis rarely persists after menopause. The disorder, for which there is no absolute cure, affects over 70 million women and girls worldwide. Often stigmatized as simply “painful periods,” Endometriosis is a puzzling and widely misunderstood illness.

It is not known exactly what causes endometriosis. But over the years several theories have been advanced to explain the probable cause of the disease although none can fully explain the various clinical manifestations of the disease. A theory proposed by John Sampson in the 1920s, suggests that endometriosis may result from something called “retrograde menstrual flow”, in which some of the tissue that a woman sheds during her period flows back through the tubes and grows in the pelvic cavity. While studies show that retrograde menstrual flow is a universal phenomenon among women of reproductive age, the theory fall short of explaining why the tissues survive in some women, but fail in others. Another theory proposed by Iwanoff in 1898, claims that, the transformation of what we call coelomic epithelium into endometrial-like tissue may be a cause of endometriosis. This theory has been supported by experimental data. The induction theory, proposes that an endogenous factor can induce peritoneal cells to develop into endometrial tissue. This theory has been supported by experiments in rabbits.



Lymphatic or vascular hypothesis suggests that endometrial fragments may be transported through blood vessels or the lymphatic system to other parts of the body. This theory speculates how endometriosis ends up in distant sites, such as the lung, brain, or the skin. A genetic linkage has been adduced which claims that, this disease could be inherited, or result from genetic errors, making some women more prone to develop the condition than others.



Studies show that the risk of endometriosis is seven times greater if the disease has affected a first-degree relative. This theory has been supported by experiments in mouse model but has not been verified either in women. Immunological etiology (cause) has also been conjured since studies report that many women with endometriosis exhibit immunological abnormalities. It is speculated that the immune system may fail to clear the menstrual debris in the pelvic cavity, allowing the endometrial cells to implant and develop into endometriosis.



Also most scientists agree that endometriosis is exacerbated by oestrogen; a hormone involved in the thickening of the endometrium and appears to promote the growth of disease implants. Some studies have pointed out environmental factors like toxins may contribute to the development of endometriosis, though this theory has not been confirmed and remains controversial.



The most common symptoms of endometriosis are abdominal pain and infertility. Some studies have reported that endometriosis may occur in 30%-40% of women with infertility and the incidence of endometriosis in women with pelvic pain may be higher than 50%.



Endometriosis associated pain may include but not limited to extremely painful (disabling) menstrual cramps, chronic pelvic pain (which includes lower back pain and pelvic pain), pain during or after sex, painful bowel movements or painful urination during menstrual periods, heavy menstrual periods and bleeding between periods. The amount of pain a women feels is sometimes not linked to degree of endometriosis. Some women have no pain even though their disease is extensive, while others have severe chronic pelvic pain even though they have only few affected areas.

The relation between endometriosis and pain is still shrouded in the mist of intricate puzzle and ignorance. Many women with endometriosis feel pain during their periods. Normally, a woman’s menstrual cycle involves her endometrial tissue to build up, breaks down into blood and tissue debris, and is shed as her menstrual flow or period. This cycle of growth and shedding happens every month under normal condition. Endometriosis grows outside the uterus and also goes through a similar cycle, build-up, breakdown and bleed every month. The problem is the tissue is in the wrong place and can’t leave the body the way a woman’s period normally does. Studies show that as part of this process, endometriosis may spur the production of substances that may irritate the nearby tissue, as well as provoke the release of chemicals that cause or mediate pain. Over time, endometriosis areas can grow and become nodules or bumps on the surface of pelvic organs, or become cysts (fluid-filled sacs) in the ovaries and may cause the organs in the pelvic area to adhere together.

Endometriosis is more than just simple "killer" cramps. Women and girls around the world continue to suffer in silence with a disease that can be potentially devastating to every aspect of their lives. It can be so painful as to render a woman or teenager unable to care for herself or her family, attend work, school, or social functions, or go about her normal routine. Endometriosis has a negative impact on the individual quality of life, affecting both physical and emotional well-being. A study by the American Endometriosis Association, demonstrated that 81% of the endometriosis patients in USA were unable to work, including household chores, because of pelvic pain. Approximately 27% were incapacitated for 3 or more days and 87% complained of fatigue or low energy. These figures are indicators of enormous suffering, in addition to the healthcare costs incurred. The need to develop intervention strategies is eminent, a published poll reveals women have to wait an average of 11.7 years in US and 8 years in UK to get a correct diagnosis after the initial onset of symptoms and a patient will seek the counsel of five or more physicians before her pain is adequately addressed and diagnosed. Once diagnosed, it is not unusual for a patient to undergo repeat surgeries and embark on many different medical therapies in an attempt to treat her symptoms. Endometriosis is a bit puzzling. We do not know why it causes such extreme symptoms in some women, while less in others. The treatment options can sometimes be unsuccessful. Sadly, endometriosis is associated with menstruation, sex, infertility, and pain (taboos in many societies), thus it is a disease that is not well known, understood, or accepted in the general public. This is frustrating for those who suffer from endometriosis, and for those who care for someone with the disease.

There is no non-invasive test to diagnose endometriosis. In fact, the only gold standard diagnosis of endometriosis is a surgical procedure known as laparoscopy and confirm histologically by taking a biopsy of the suspicious tissue.

However, this is an expensive, minimally invasive procedure. Furthermore, a specialised surgeon is needed for adequate assessment of the pelvis, for recognition of the various types and appearances of the disease. If the patients decline surgery, this makes diagnosis a challenge, and therefore an experienced gynaecologist should be able to recognise symptoms suggestive of endometriosis. The fact that there is no non-invasive diagnostic test for endometriosis is frustrating for clinicians as well as for women with the disease and underscores the need for search of better diagnostic tools.

Since the cause of endometriosis remains unknown, a treatment that fully cures the disease is yet to be developed. Choosing a holistic, treatment option comes down to the individual woman's needs, depending on symptoms, age, and reproductive desires.

Pain is the most common symptom in many women with endometriosis, mainly managed by painkillers, which may vary from simple analgesics to non-steroidal anti-inflammatory drugs. Most researchers agree that endometriosis is exacerbated by oestrogen. Subsequently, hormonal treatments for endometriosis attempt to reverse oestrogen production in a woman's body and thereby alleviate symptoms. However, hormonal therapies have varying degrees of side effects, and unfortunately, whatever pain relief is achieved tends to be only temporary for many women. Most gynaecologists agree that laparoscopic surgery is the only way to diagnose and treat endometriosis. Laparoscopy involves a small cut or incision in the abdomen, inflating the abdomen with harmless gas, and then inserts a viewing instrument with help of light (Laparoscope) into the abdomen. The success of surgery depends largely on the skills of the surgeon and the thoroughness of the surgery. The aim is to remove all endometriosis lesions, cysts, and adhesions. Today, most endometriosis surgery is being done through the laparoscopy, although a full abdominal incision called a laparotomy may still be required in rare cases for extensive disease or bowel resections.

Although the prevalence of endometriosis is well documented in women living in the developed world, studies among African women are still limited. The current myth is that endometriosis rarely affects women of African origin. However, among African-American women in the USA, studies have shown endometriosis is one of the common indications for major gynaecological surgery and hysterectomy, and is associated with a high hospital costs. Although genetically, African-American and African women from the African continent are not necessarily identical given the known genetic admixture among the African-American population. Lack of awareness of endometriosis as a potentially disabling disease and poor access to state-of art diagnostic and therapeutic facilities has contributed to the meagre data on prevalence of the disease in the African population. There is need to initiate awareness campaign of endometriosis to reach all women in Africa. Also to highlight the general lack of information, facilitate endometriosis research efforts and draw attention to the impact and implications of the disease to healthcare systems in our country and the continent in general.

The writer is a Senior Scientist with special interest in endometriosis and ovarian cancer research

http://www.africasciencenews.org/en/index.php/health/63-health/194-endometriosis-slowly-emerges-as-a-life-threatening-disease-for-women
Posted by itsme at 12:24 PM No comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: ARD, endo, endometriomas, endometriosis, Endometrium, excise, laparoscopy, lesions, Lung endometriosis, Lupron, pelvic pain, Postmenopausal, questionable medical practices, unnecessary hysterectomy

Saturday, November 12, 2011

sharing my experience with the robotic laparoscopy and endometriosis




http://www.youtube.com/watch?v=lTCMy4k9qrE&feature=related 
Posted by itsme at 6:36 AM 2 comments:
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: adhesion related disorder, adhesions, endo, endometriomas, endometriosis, Endometrium, laparoscopy, pain, pelvic pain, robotic surgery, scar tissue
Older Posts Home
Subscribe to: Posts (Atom)

Translate


Search This Blog

Links

  • EndoTimes Home
  • World Endometriosis Society
  • World Endometriosis Research Foundation
  • Endometriosis Association
  • Endo Friendo
  • LIVING WITH LUNG AND COLON ENDOMETRIOSIS
  • endometriosis.org
  • ARDvark Blog
  • Adhesion Related Disorder
  • International Adhesion Society
  • IHRT Blog

Subscribe To

Posts
Atom
Posts
All Comments
Atom
All Comments

Blog Archive

  • ▼  2017 (2)
    • ▼  August (2)
      • ARDvark Blog Journal of Adhesion Related Disorde...
      • ARDvark Blog Journal of Adhesion Related Disorde...
  • ►  2016 (2)
    • ►  March (2)
  • ►  2015 (1)
    • ►  January (1)
  • ►  2014 (59)
    • ►  July (1)
    • ►  May (6)
    • ►  April (18)
    • ►  March (32)
    • ►  January (2)
  • ►  2013 (12)
    • ►  December (10)
    • ►  October (2)
  • ►  2012 (20)
    • ►  May (1)
    • ►  March (1)
    • ►  February (7)
    • ►  January (11)
  • ►  2011 (91)
    • ►  December (7)
    • ►  November (13)
    • ►  October (19)
    • ►  September (22)
    • ►  August (8)
    • ►  July (2)
    • ►  June (3)
    • ►  May (3)
    • ►  April (3)
    • ►  March (8)
    • ►  February (3)
  • ►  2010 (3)
    • ►  February (3)
  • ►  2009 (7)
    • ►  June (2)
    • ►  May (1)
    • ►  February (2)
    • ►  January (2)
  • ►  2008 (61)
    • ►  November (3)
    • ►  October (2)
    • ►  September (5)
    • ►  August (6)
    • ►  June (3)
    • ►  May (3)
    • ►  April (2)
    • ►  March (2)
    • ►  February (11)
    • ►  January (24)
  • ►  2007 (122)
    • ►  December (7)
    • ►  June (16)
    • ►  May (8)
    • ►  April (17)
    • ►  March (25)
    • ►  February (13)
    • ►  January (36)
  • ►  2006 (119)
    • ►  December (33)
    • ►  November (33)
    • ►  October (9)
    • ►  September (4)
    • ►  June (1)
    • ►  April (39)
Powered By Blogger
*Bloggers may have controversial opinions about public figures & news. If you think our opinions will offend you, do NOT read them. Do not visit this site. The information provided in this site is not intended to substitute any professional medical advice and services. Seek the advice of a qualified health provider when starting any new medical intervention or with any questions you may have regarding medical conditions.
Simple theme. Powered by Blogger.